GlaxoSmithKline’s drisapersen (previously GSK2402968/PRO051) to receive Food and Drug Administration Breakthrough Therapy designation for potential treatment of patients with Duchenne Muscular Dystrophy

Breakthrough Therapy designation is one of several programmes created by the FDA to expedite the development and review of drugs for serious or life-threatening conditions.
Source: GSK news - Category: Pharmaceuticals Source Type: news